Market Place
Sourcing Support
Compass Pathways to Participate in December Investor Conferences
25 Nov 2024 //
BUSINESSWIRE
Compass Pathways to Participate in Stifel Healthcare Conference
14 Nov 2024 //
GLOBENEWSWIRE
Compass delays phase 3 psychedelic data, lays off 30% of staff
31 Oct 2024 //
FIERCE BIOTECH
Compass Pathways To Announce Q3 Financial Results On Oct 31
24 Oct 2024 //
BUSINESSWIRE
Compass Pathways To Join Cowen Psychedelics Summit
23 Sep 2024 //
BUSINESSWIRE
Compass Pathways to participate in three investor conferences in September
28 Aug 2024 //
GLOBENEWSWIRE
COMPASS Pathways To Participate In Canaccord Genuity Conference
06 Aug 2024 //
GLOBENEWSWIRE
Compass Pathways Reports Q2 2024 Results And Business Highlights
01 Aug 2024 //
GLOBENEWSWIRE
Compass Pathways to announce second quarter financial results on August 1, 2024
24 Jul 2024 //
GLOBENEWSWIRE
Compass Pathways appoints Lori Englebert as Chief Commercial Officer
26 Jun 2024 //
GLOBENEWSWIRE
Compass Pathways To Join H.C. Wainwright Neuro Perspectives Conference
24 Jun 2024 //
GLOBENEWSWIRE
US FDA panel votes against first MDMA-based PTSD treatment
05 Jun 2024 //
REUTERS
Compass tracks PTSD improvements in midphase psilocybin trial
09 May 2024 //
FIERCE BIOTECH
Compass PTSD COMP360 Psilocybin 12-Week Durability Data
08 May 2024 //
GLOBENEWSWIRE
Compass Pathways Q1 2024 Results, Business Highlights
08 May 2024 //
GLOBENEWSWIRE
US FDA panel to discuss first psychedelic-assisted PTSD treatment next month
07 May 2024 //
REUTERS
Compass Pathways to announce first quarter financial results on May 8, 2024
03 May 2024 //
GLOBENEWSWIRE
Compass, Mindful On COMP360 Psilocybin Delivery Model
02 May 2024 //
GLOBENEWSWIRE
Compass, Journey Collab on COMP360 Psilocybin Provider Training Model
29 Apr 2024 //
GLOBENEWSWIRE
Compass Pathways to participate in upcoming Healthcare Conference
01 Apr 2024 //
GLOBENEWSWIRE
Compass Pathways Board Chair and Co-Founder Goldsmith and Malievskaia Step Down
28 Mar 2024 //
GLOBENEWSWIRE
Compass Announces Fourth Quarter 2023 Financial Results and Business Highlights
29 Feb 2024 //
GLOBENEWSWIRE
Compass Pathways to participate in upcoming TD Cowen investor conference
26 Feb 2024 //
GLOBENEWSWIRE
Compass Pathways to announce fourth quarter and year-end 2023 financial results
22 Feb 2024 //
GLOBENEWSWIRE
Compass Pathways to participate in upcoming Oppenheimer investor conference
31 Jan 2024 //
GLOBENEWSWIRE
Compass, Hackensack Meridian ink research deal for psilocybin
17 Jan 2024 //
FIERCE BIOTECH
Compass Pathways enters into collaboration agreement with Hackensack Meridian
16 Jan 2024 //
GLOBENEWSWIRE
Compass Pathways and Greenbrook TMS enter into research collaboration agreement
05 Jan 2024 //
GLOBENEWSWIRE
Compass shows safety in first psilocybin trial for PTSD
20 Dec 2023 //
FIERCE BIOTECH
Compass announces COMP360 psilocybin treatment was well-tolerated in ph 2 study
19 Dec 2023 //
GLOBENEWSWIRE
Compass Pathways appoints Teri Loxam as Chief Financial Officer
07 Dec 2023 //
GLOBENEWSWIRE
Study results of psilocybin treatment in bipolar II depression published in JAMA
06 Dec 2023 //
GLOBENEWSWIRE
Compass Pathways to participate in upcoming Evercore investor conference
24 Nov 2023 //
GLOBENEWSWIRE
Compass initiates UK component of global phase 3 study of psilocybin treatment
15 Nov 2023 //
GLOBENEWSWIRE
COMPASS Pathways Announces Third Quarter 2023 Financial Results
02 Nov 2023 //
GLOBENEWSWIRE
COMPASS Pathways announces CFO transition
26 Oct 2023 //
GLOBENEWSWIRE
COMPASS Pathways plc to Announce Third Quarter 2023 Financial Results
24 Oct 2023 //
GLOBENEWSWIRE
COMPASS Pathways appoints Daphne Karydas to its Board of Directors
18 Sep 2023 //
GLOBENEWSWIRE
COMPASS announces publication of first study evaluating potential of AI model
06 Sep 2023 //
GLOBENEWSWIRE
COMPASS Pathways to participate in upcoming September investor conferences
29 Aug 2023 //
GLOBENEWSWIRE
COMPASS Pathways Announces Up to $285 Million Private Placement Financing
16 Aug 2023 //
GLOBENEWSWIRE
COMPASS Pathways Announces Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
COMPASS Pathways plc to announce second quarter 2023 financial results
31 Jul 2023 //
GLOBENEWSWIRE
First study results of psilocybin treatment in anorexia nervosa published
25 Jul 2023 //
GLOBENEWSWIRE
COMPASS Pathways announces publication of data from PII of COMP360 psilocybin
17 Jul 2023 //
GLOBENEWSWIRE
Opinion paper calls for clarity on the definition of “psychedelic-assisted therapy”
13 Jul 2023 //
GLOBENEWSWIRE
American Medical Association Releases Language of First New Current Terminology
06 Jul 2023 //
GLOBENEWSWIRE
COMPASS Pathways Secures Term Loan Facility for Up to $50M from Hercules Capital
05 Jul 2023 //
GLOBENEWSWIRE
COMPASS Pathways to participate in upcoming Cantor Fitzgerald and HC Wainwright
16 Jun 2023 //
GLOBENEWSWIRE
COMPASS Pathways Co-Founder Ekaterina Malievskaia to Step Down as CIO
31 May 2023 //
GLOBENEWSWIRE
Data Showing Improvement in Depression Following Single Dose of COMP360 to be Presented
26 May 2023 //
GLOBENEWSWIRE
COMPASS Pathways to participate in upcoming Jefferies Healthcare Conference
26 May 2023 //
GLOBENEWSWIRE
COMPASS Pathways Announces First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
COMPASS Pathways plc to announce 1Q 2023 financial results on 11 May 2023
03 May 2023 //
GLOBENEWSWIRE
American Medical Association to Issue First New Code for Psychedelic Therapies
02 May 2023 //
GLOBENEWSWIRE
Compass Pathways to participate in 22nd Annual Needham Healthcare Conference
10 Apr 2023 //
GLOBENEWSWIRE
COMPASS to participate in upcoming Cowen 43rd Annual Health Care Conference
02 Mar 2023 //
GLOBENEWSWIRE
COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results
28 Feb 2023 //
GLOBENEWSWIRE
COMPASS Pathways to announce fourth quarter and year-end 2022 financial results
24 Feb 2023 //
GLOBENEWSWIRE
COMP360 psilocybin therapy shows potential in study in type II bipolar disorder
08 Dec 2022 //
GLOBENEWSWIRE
